Geode Capital Management LLC Raises Position in Kamada Ltd. (NASDAQ:KMDA)

Geode Capital Management LLC boosted its position in shares of Kamada Ltd. (NASDAQ:KMDA) by 5.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 29,289 shares of the biotechnology company’s stock after buying an additional 1,549 shares during the period. Geode Capital Management LLC owned 0.05% of Kamada worth $178,000 at the end of the most recent quarter.

Separately, JPMorgan Chase & Co. purchased a new stake in shares of Kamada during the fourth quarter worth approximately $67,000. 20.38% of the stock is currently owned by institutional investors and hedge funds.

Kamada Stock Performance

NASDAQ KMDA opened at $6.66 on Friday. The stock’s fifty day moving average is $6.63 and its two-hundred day moving average is $6.50. The firm has a market capitalization of $382.82 million, a P/E ratio of 23.79, a price-to-earnings-growth ratio of 0.97 and a beta of 1.08. Kamada Ltd. has a fifty-two week low of $4.74 and a fifty-two week high of $9.16.

Kamada Dividend Announcement

The company also recently declared a — dividend, which was paid on Monday, April 7th. Stockholders of record on Monday, March 17th were given a dividend of $0.20 per share. The ex-dividend date of this dividend was Monday, March 17th.

Analysts Set New Price Targets

KMDA has been the topic of a number of research reports. StockNews.com lowered Kamada from a “strong-buy” rating to a “buy” rating in a report on Tuesday, March 25th. HC Wainwright reissued a “buy” rating and issued a $11.00 price target on shares of Kamada in a research note on Thursday, March 6th. Finally, Benchmark assumed coverage on shares of Kamada in a research note on Friday, March 21st. They set a “buy” rating and a $15.00 price objective for the company.

Kamada Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.